Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced extreme volatility, with an initial surge of over 60% to a peak of 679.5 HKD per share, followed by a sharp decline of over 60% to a low of 165 HKD per share, resulting in a total intraday fluctuation exceeding 120% [1][2][4]. Group 1: Stock Performance - The stock reached a market capitalization close to 270 billion HKD before plummeting to below 70 billion HKD by the end of the trading day [1][2]. - The closing price was reported at 192 HKD per share, reflecting a decline of 53.73% from its earlier peak [2]. Group 2: Company Announcements -药捷安康 issued a statement acknowledging the unusual stock price and trading volume fluctuations, confirming no significant changes in its business operations or financial status [4]. - The board of directors stated they were unaware of any reasons for the stock price movements or any information that should be disclosed to prevent a false market [4]. Group 3: Company Background and Financials -药捷安康 went public on June 23, with an initial offering price of 13.15 HKD per share, and has seen its stock price increase significantly since then, with a reported increase of 5067% from the IPO price [5][6]. - The company remains in a loss-making position, with a pre-tax loss of 123 million HKD for the first half of the year, an improvement from a loss of 160 million HKD in the same period the previous year [7]. - Other income and revenue dropped by 65.1% to 3.6 million HKD, primarily due to reduced bank interest and government subsidies [7].
刚刚，2000亿大绞杀！